The team will continue studying inequities in GLP-1 access for diabetic and non-diabetic populations, including potential differences by socioeconomic status, race and ethnicity, and Medicare and Medicaid coverage
Afamelanotide (Scenesse, Clinuvel Pharmaceuticals) is a linear MC1R selective tridecapeptide, approved by the FDA on October 8, 2019, and by the EMA on December 22, 2014, exclusively for the treatment of erythropoietic protoporphyria (EPP) in adults
General peptide behavior studies help advance understanding of molecular interactions and stability factors
heart attack, stroke) in adults with type 2 diabetes and heart disease Reduce the risk of kidney decline in adults with type 2 diabetes and chronic kidney disease And Wegovy is FDA-approved to: Reduce excess body weight and manage weight long term in adults and children ages 12+ with obesity as well as adults with obesity or overweight who have at least one weight-related health condition (e.g
A healthy lifestyle WHO recommendations